

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: S. TOJI et al.

Serial No.: 09/830,706

Filed: August 7, 2001

For: THIOREDOXIN REDUCTASE II

GROUP: Not Yet Assigned

EXAMINER: Not Yet Assigned

RECEIVED

JUL 18 2002


Assistant Commissioner for Patents

Washington, D.C. 20231

TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: BOX IDS Commissioner for Patents, Washington, D.C. 20231.

Date October 22, 2001By: 

Judith A. Herrick

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §§1.56 and 1.97, Applicants herewith submit the publications and/or patents shown on the attached form PTO-1449, for consideration by the Examiner in connection with the examination of the above-identified patent application.

REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed:

(1) within three (3) months of the Filing Date or **before the mailing date of the First Office Action** on the merits; or

(2) within three months of the mailing date of the Search Report issued by the: _____ Patent Office (dated _____) (**COPY ENCLOSED**); or

(3) after the period defined in (1) but before the mailing date of a **Final Rejection or Notice of Allowance**, and the requisite Certification or fee under Rule 1.17(p), namely \$240.00, is included herein; or

— (4) after the mailing date of a **Final Rejection or Notice of Allowance** but before the payment of the **Issue Fee**, and the requisite Certification, petition, and petition fee are included herein.

It is respectfully requested that each of the documents shown on the attached form(s) PTO-1449 be made of record in this application. Copies of these documents (CHECK ONE):

are enclosed herewith; or
 have been cited in the parent application, and are thus not being resubmitted herewith
 each reference was cited in a European Search Report (copy enclosed).

RECEIVED

JUL 18 2002

TECH CENTER 1600/2900

Early examination and allowance of the present application are respectfully solicited.

FEE AUTHORIZATION

Should any fees associated with the submission be required, the Commissioner is authorized to charge the missing fee to our Deposit Account, No. 04-1105. Any overpayments should be credited to said Deposit Account.

Respectfully submitted,



Peter F. Corless (Reg. 33,860)
Edwards & Angell, LLP
P.O. Box 9169
Boston, MA 02209
(617) 439-4444

Date: October 22, 2001



FORM PTO-1449 (10-02-00) INFORMATION DISCLOSURE STATEMENT	DOCKET NO.: 55865 (71965)	SERIAL NO.: 09/830,706
	APPLICANT(S): S. TOJI et al.	
	FILING DATE: August 7, 2001	GROUP NO.: Not Yet Assigned

UNITED STATES PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

	AA	Rothe M. et al. <u>The TNFR2-TRAF Signaling Complex Contains Two Novel Proteins Related to Baculoviral Inhibitor of Apoptosis Proteins</u> , Cell, Vol 83(7), pp 1243-1252, 1995;
	AB	Holmgren A. <u>THIOREDOXIN</u> , Annu Rev Biochem, Vol 54, pp 237-271, 1985;
	AC	Silverman R.B. et al. <u>REDUCED THIOREDOXIN: A POSSIBLE PHYSIOLOGICAL COFACTOR FOR VITAMIN K EPOXIDE REDUCTASE. FURTHER SUPPORT FOR AN ACTIVE SITE DISULFIDE</u> , Biochem Biophys Res Commun, Vol 155(3), pp. 1248-1254, 1988;
	AD	Hayashi T, et al. <u>Oxidoreductive Regulation of Nuclear Factor κ B</u> , J Biol Chem, Vol 268(15), pp 11380-11388, 1993;
	AE	Matthews J.R. et al., <u>Thioredoxin regulates the DNA binding activity of NF-κ B by reduction of a disulphide bond involving cysteine 62</u> , Nucleic Acids Res, Vol 20(15), pp 3821-3830, 1992;

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		DOCKET NO.: 55865 (71965)	SERIAL NO.: 09/830,706
		APPLICANT(S): S. TOJI et al.	
		FILING DATE: August 7, 2001	GROUP NO.: Not Yet Assigned
AF	Bannister A.J., et al. <u>In vitro DNA binding activity of Fos/Jun and BZLF1 but not C/EBP is affected by redox changes</u> , Oncogene, Vol 6(7), pp. 1243-1250, 1991;		
AG	Zhong L., et al. <u>Rat and Calf Thioredoxin Reductase Are Homologous to Glutathione Reductase with a Carboxyl-terminal Elongation Containing a Conserved Catalytically Active Penultimate Selenocysteine Residue</u> , J Biol Chem, Vol 273(15), pp. 8581-8591, 1998;		
AH	Ito W., et al. <u>A general method for introducing a series of mutations into cloned DNA using the polymerase chain reaction</u> , Gene, Vol 102(1), pp. 67-70, 1991;		
AI	Gromer S., et al., <u>Human Placenta Thioredoxin Reductase</u> , J Biol Chem, Vol 273(32), pp. 20096-20101, 1998;		
AJ	Mustacich D., et al. <u>Thioredoxin reductase</u> , Biochem J., Vol 346, pp. 1-8, 2000;		
AK	Lescure A., et al. <u>Novel Selenoproteins Identified in Silico and in Vivo by Using a Conserved RNA Structural Motif</u> , J Biol Chem, Vol 274(53), pp. 38147-38154, 1999;		
AL	Miranda-Vizuete A., et al. <u>cDNA cloning, expression and chromosomal localization of the mouse mitochondrial thioredoxin reductase gene</u> , Biochim Biophys Acta, Vol 1447(1), pp. 113-118, 1999;		
AM	Miranda-Vizuete A., et al. <u>Human mitochondrial thioredoxin reductase</u> , Eur J Biochem, Vol 261(2) pp. 405-412, 1999;		
AN	Gasdaska P.Y., et al. <u>Cloning, sequencing and functional expression of a novel human thioredoxin reductase</u> , FEBS Lett, Vol 442(1), pp. 105-111, 1999;		
AO	Becker K., et al. <u>Human Thioredoxin Reductase Is Efficiently Inhibited by (2,2':6',2"-Terpyridine) platinum(II) Complexes. Possible Implications for a Novel Antitumor Strategy</u> , J Med Chem, Vol 44(17), pp. 2784-2792, 2001;		
AP	Hu J., et al. <u>Modulation of p53 dependent gene expression and cell death through thioredoxin-thioredoxin reductase by the Interferon-Retinoid combination</u> , Oncogene, Vol 20(31), pp. 4235-4248, 2001;		
AQ	Soini Y., et al. <u>Widespread Expression of Thioredoxin and Thioredoxin Reductase in Non-Small Cell Lung Carcinoma</u> , Clin Cancer Res, Vol 7(6), pp. 1750-1757, 2001		
AR	<u>UP-REGULATION OF THIOREDOXIN AND THIOREDOXIN REDUCTASE IN HUMAN MALIGNANT PLEURAL MESOTHELIOMA</u> , Int J Cancer, Vol 95(3), pp. 198-204, 2001		
AS			
AT			
Examiner:		Date:	

RECEIVED
JUL 18 2002
TECH CENTER 1600/2900